Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin | Zendy

Anthony J. Busti | Zendy; Amy M. Bain | Zendy; Ronald G. Hall | Zendy; Roger Bedimo | Zendy; Richard D. Leff | Zendy; Claudia Meek | Zendy; Reza Mehvar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin

Author(s) -

Anthony J. Busti,

Amy M. Bain,

Ronald G. Hall,

Roger Bedimo,

Richard D. Leff,

Claudia Meek,

Reza Mehvar

Publication year - 2008

Publication title -

journal of cardiovascular pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.762

H-Index - 100

eISSN - 1533-4023

pISSN - 0160-2446

DOI - 10.1097/fjc.0b013e31817b5b5a

Subject(s) - ritonavir , rosuvastatin , pharmacokinetics , cmax , lopinavir , atazanavir , pharmacology , rosuvastatin calcium , bioavailability , medicine , lopinavir/ritonavir , viral load , virology , human immunodeficiency virus (hiv) , antiretroviral therapy

Rosuvastatin (RSV) is a potent statin with a lower potential for drug interactions. However, recent data have revealed unexpected increases in RSV concentrations with lopinavir/ritonavir. The objective is to study the pharmacokinetic interaction of RSV with atazanavir/ritonavir (ATV/RTV) or fosamprenavir/ritonavir (FPV/RTV).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research